| Cover | 12 Months Ended |
| Dec. 31, 2022 | |
| Document Information [Line Items] | |
| Document Type | PREC14A |
| Amendment Flag | false |
| Entity Information [Line Items] | |
| Entity Registrant Name | EXELIXIS, INC. |
| Entity Central Index Key | 0000939767 |
| Pay vs Performance Disclosure - USD ($) | 12 Months Ended | ||
| Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Pay vs Performance Disclosure [Table] | |||
| Pay vs Performance [Table Text Block] | Required Tabular Disclosure of Pay Versus Performance The amounts set forth below under the headings “Compensation Actually Paid to PEO” and “Average Compensation Actually Paid to Non-PEO S-K. Year Summary (1) ($) Compensation (1)(2) ($) Average Non-PEO (1) ($) Average Non-PEO (1)(2) ($) Value of Initial Fixed $100 Net Income ($) Net Product (5) ($) Total (3) ($) Peer Group (4) ($) 2022 16,877,545 16,020,538 5,149,608 5,038,751 94 116 182.3 1,401.2 2021 7,530,431 15,297,662 3,510,384 5,612,040 107 129 231.1 1,077.3 2020 2,349,812 18,565,411 1,237,199 5,878,678 118 129 111.8 741.6 (1) Dr. Morrissey was our PEO for each year presented. The individuals comprising the non-PEO (2) Compensation actually paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO Year Summary Compensation PEO ($) Exclusion of Stock Awards ($) Inclusion of Equity Values for ($) Compensation Actually Paid ($) 2022 16,877,545 (14,567,256 ) 13,710,249 16,020,538 2021 7,530,431 (5,160,513 ) 12,927,744 15,297,662 2020 2,349,812 0 16,215,599 18,565,411 Year Average Summary Non-PEO ($) Average Exclusion of Stock Non-PEO ($) Average Inclusion of Equity Non-PEO ($) Average Compensation Actually Paid to Non-PEO ($) 2022 5,149,608 (4,061,664 ) 3,950,807 5,038,751 2021 3,510,384 (2,641,508 ) 4,743,164 5,612,040 2020 1,237,199 (190,750 ) 4,832,229 5,878,678 The amounts in the “Inclusion of Equity Values” columns in the tables above are derived from the amounts set forth in the following tables: Year Year End Fair ($) Year over Year ($) Fair Value as of ($) Year over Year ($) Fair Value at Last ($) Total – Inclusion ($) 2022 11,008,595 1,591,223 0 1,110,432 0 13,710,249 2021 6,464,669 3,180,756 0 3,282,318 0 12,927,744 2020 0 7,832,719 0 8,382,880 0 16,215,599 Year Average Year End Non-PEO NEOs ($) Average Year over Non-PEO ($) Average Fair Value Non-PEO ($) Average Year over for Non-PEO NEOs ($) Average Fair Value Non-PEO ($) Total – Average Non-PEO ($) 2022 3,080,814 443,853 123,352 302,788 0 3,950,807 2021 1,324,859 721,634 288,187 2,408,484 (a) 0 4,743,164 2020 175,613 2,259,042 0 2,397,575 0 4,832,229 (a) Amount includes the addition of the aggregate incremental fair value associated with the modifications of Dr. Schwab’s equity awards in September 2021. (3) Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end and the beginning of the measurement period by our share price at the beginning of the measurement period. The beginning of the measurement period for each year in the table is January 3, 2020. (4) The peer group used for this purpose is the Nasdaq Biotechnology Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the fiscal year ended December 30, 2022. (5) SEC rules require us to designate a “Company-Selected Measure” that in our assessment represents the most important financial performance measure used by us to link the compensation actually paid to our PEO and non-PEO | ||
| Company Selected Measure Name | Net Product Revenues | ||
| Named Executive Officers, Footnote [Text Block] | (1) Dr. Morrissey was our PEO for each year presented. The individuals comprising the non-PEO | ||
| Peer Group Issuers, Footnote [Text Block] | (4) The peer group used for this purpose is the Nasdaq Biotechnology Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the fiscal year ended December 30, 2022. | ||
| PEO Total Compensation Amount | $ 16,877,545 | $ 7,530,431 | $ 2,349,812 |
| PEO Actually Paid Compensation Amount | $ 16,020,538 | 15,297,662 | 18,565,411 |
| Adjustment To PEO Compensation, Footnote [Text Block] | (2) Compensation actually paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO Year Summary Compensation PEO ($) Exclusion of Stock Awards ($) Inclusion of Equity Values for ($) Compensation Actually Paid ($) 2022 16,877,545 (14,567,256 ) 13,710,249 16,020,538 2021 7,530,431 (5,160,513 ) 12,927,744 15,297,662 2020 2,349,812 0 16,215,599 18,565,411 Year Average Summary Non-PEO ($) Average Exclusion of Stock Non-PEO ($) Average Inclusion of Equity Non-PEO ($) Average Compensation Actually Paid to Non-PEO ($) 2022 5,149,608 (4,061,664 ) 3,950,807 5,038,751 2021 3,510,384 (2,641,508 ) 4,743,164 5,612,040 2020 1,237,199 (190,750 ) 4,832,229 5,878,678 The amounts in the “Inclusion of Equity Values” columns in the tables above are derived from the amounts set forth in the following tables: Year Year End Fair ($) Year over Year ($) Fair Value as of ($) Year over Year ($) Fair Value at Last ($) Total – Inclusion ($) 2022 11,008,595 1,591,223 0 1,110,432 0 13,710,249 2021 6,464,669 3,180,756 0 3,282,318 0 12,927,744 2020 0 7,832,719 0 8,382,880 0 16,215,599 Year Average Year End Non-PEO NEOs ($) Average Year over Non-PEO ($) Average Fair Value Non-PEO ($) Average Year over for Non-PEO NEOs ($) Average Fair Value Non-PEO ($) Total – Average Non-PEO ($) 2022 3,080,814 443,853 123,352 302,788 0 3,950,807 2021 1,324,859 721,634 288,187 2,408,484 (a) 0 4,743,164 2020 175,613 2,259,042 0 2,397,575 0 4,832,229 (a) Amount includes the addition of the aggregate incremental fair value associated with the modifications of Dr. Schwab’s equity awards in September 2021. | ||
| Non-PEO NEO Average Total Compensation Amount | $ 5,149,608 | 3,510,384 | 1,237,199 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ 5,038,751 | 5,612,040 | 5,878,678 |
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | (2) Compensation actually paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO Year Summary Compensation PEO ($) Exclusion of Stock Awards ($) Inclusion of Equity Values for ($) Compensation Actually Paid ($) 2022 16,877,545 (14,567,256 ) 13,710,249 16,020,538 2021 7,530,431 (5,160,513 ) 12,927,744 15,297,662 2020 2,349,812 0 16,215,599 18,565,411 Year Average Summary Non-PEO ($) Average Exclusion of Stock Non-PEO ($) Average Inclusion of Equity Non-PEO ($) Average Compensation Actually Paid to Non-PEO ($) 2022 5,149,608 (4,061,664 ) 3,950,807 5,038,751 2021 3,510,384 (2,641,508 ) 4,743,164 5,612,040 2020 1,237,199 (190,750 ) 4,832,229 5,878,678 The amounts in the “Inclusion of Equity Values” columns in the tables above are derived from the amounts set forth in the following tables: Year Year End Fair ($) Year over Year ($) Fair Value as of ($) Year over Year ($) Fair Value at Last ($) Total – Inclusion ($) 2022 11,008,595 1,591,223 0 1,110,432 0 13,710,249 2021 6,464,669 3,180,756 0 3,282,318 0 12,927,744 2020 0 7,832,719 0 8,382,880 0 16,215,599 Year Average Year End Non-PEO NEOs ($) Average Year over Non-PEO ($) Average Fair Value Non-PEO ($) Average Year over for Non-PEO NEOs ($) Average Fair Value Non-PEO ($) Total – Average Non-PEO ($) 2022 3,080,814 443,853 123,352 302,788 0 3,950,807 2021 1,324,859 721,634 288,187 2,408,484 (a) 0 4,743,164 2020 175,613 2,259,042 0 2,397,575 0 4,832,229 (a) Amount includes the addition of the aggregate incremental fair value associated with the modifications of Dr. Schwab’s equity awards in September 2021. (3) Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end and the beginning of the measurement period by our share price at the beginning of the measurement period. The beginning of the measurement period for each year in the table is January 3, 2020. (4) The peer group used for this purpose is the Nasdaq Biotechnology Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the fiscal year ended December 30, 2022. (5) SEC rules require us to designate a “Company-Selected Measure” that in our assessment represents the most important financial performance measure used by us to link the compensation actually paid to our PEO and non-PEO | ||
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | Compensation Actually Paid Compared to TSR | ||
| Compensation Actually Paid vs. Net Income [Text Block] | Compensation Actually Paid compared to Net Income | ||
| Compensation Actually Paid vs. Company Selected Measure [Text Block] | Compensation Actually Paid compared to Net Product Revenues | ||
| Total Shareholder Return Vs Peer Group [Text Block] | Compensation Actually Paid Compared to TSR | ||
| Tabular List [Table Text Block] | Required Tabular Disclosure of Most Important Performance Measures The most important performance measures used to link compensation actually paid to our NEOs for 2022 to Company performance are set forth below. For further information regarding these performance metrics and their function in our executive compensation program, please refer to the “Compensation Discussion and Analysis” section of this Proxy Statement. Relative TSR Net Product Revenues | ||
| Total Shareholder Return Amount | $ 94 | 107 | 118 |
| Peer Group Total Shareholder Return Amount | 116 | 129 | 129 |
| Net Income (Loss) | $ 182,300,000 | $ 231,100,000 | $ 111,800,000 |
| Company Selected Measure Amount | 1,401,200,000 | 1,077,300,000 | 741,600,000 |
| PEO Name | Dr. Morrissey | ||
| Measure [Axis]: 1 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Relative TSR | ||
| Measure [Axis]: 2 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Net Product Revenues | ||
| PEO [Member] | Exclusion of Stock Awards and Options Awards [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ (14,567,256) | $ (5,160,513) | $ 0 |
| PEO [Member] | Inclusion of Equity Values [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 13,710,249 | 12,927,744 | 16,215,599 |
| PEO [Member] | Year End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 11,008,595 | 6,464,669 | 0 |
| PEO [Member] | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 1,591,223 | 3,180,756 | 7,832,719 |
| PEO [Member] | Fair Value as of Vesting Date of Equity Awards Granted and Vested During Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 0 | 0 |
| PEO [Member] | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested During Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 1,110,432 | 3,282,318 | 8,382,880 |
| PEO [Member] | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 0 | 0 |
| Non-PEO NEO [Member] | Exclusion of Stock Awards and Options Awards [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (4,061,664) | (2,641,508) | (190,750) |
| Non-PEO NEO [Member] | Inclusion of Equity Values [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 3,950,807 | 4,743,164 | 4,832,229 |
| Non-PEO NEO [Member] | Year End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 3,080,814 | 1,324,859 | 175,613 |
| Non-PEO NEO [Member] | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 443,853 | 721,634 | 2,259,042 |
| Non-PEO NEO [Member] | Fair Value as of Vesting Date of Equity Awards Granted and Vested During Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 123,352 | 288,187 | 0 |
| Non-PEO NEO [Member] | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested During Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 302,788 | 2,408,484 | 2,397,575 |
| Non-PEO NEO [Member] | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ 0 | $ 0 | $ 0 |
